Anti-Hyperuricemic Effect of Anserine Based on the Gut–Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics
Nutrients · 2023
DOI: 10.3390/nu15040969 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Mairepaiti Halimulati und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100871, China. Hauptthemen laut MEDLINE: Hyperuricemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China.
Abstract (Originalsprache)
Nowadays, developing effective intervention substances for hyperuricemia has become a public health issue. Herein, the therapeutic ability of anserine, a bioactive peptide, was validated through a comprehensive multiomics analysis of a rat model of hyperuricemia. Anserine was observed to improve liver and kidney function and modulate urate-related transporter expressions in the kidneys. Urine metabolomics showed that 15 and 9 metabolites were significantly increased and decreased, respectively, in hyperuricemic rats after the anserine intervention. Key metabolites such as fructose, xylose, methionine, erythronic acid, glucaric acid, pipecolic acid and trans-ferulic acid were associated with ameliorating kidney injury. Additionally, anserine regularly changed the gut microbiota, thereby ameliorating purine metabolism abnormalities and alleviating inflammatory responses. The integrated multiomics analysis indicated that Saccharomyces, Parasutterella excrementihominis and Emergencia timonensis were strongly associated with key differential metabolites. Therefore, we propose that anserine improved hyperuricemia via the gut–kidney axis, highlighting its potential in preventing and treating hyperuricemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100871, China.
- Beijing's Key Laboratory of Food Safety Toxicology Research and Evaluation, Beijing 100871, China.
- Division of Molecular and Cellular Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Wenli Zhu, Zhaofeng Zhang, Lixia He
Förderung
- National Key R&D Program of China
Zitieren
APA
Halimulati, M., Wang, R., Aihemaitijiang, S., Huang, X., Ye, C., Zhang, Z., Li, L., Zhu, W., Zhang, Z., & He, L. (2023). Anti-Hyperuricemic Effect of Anserine Based on the Gut–Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics. Nutrients. https://doi.org/10.3390/nu15040969
Vancouver
Halimulati M, Wang R, Aihemaitijiang S, Huang X, Ye C, Zhang Z, et al. Anti-Hyperuricemic Effect of Anserine Based on the Gut–Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics. Nutrients. 2023. doi:10.3390/nu15040969
BibTeX
@article{Halimulati2023,
author = {Halimulati, Mairepaiti and Wang, Ruoyu and Aihemaitijiang, Sumiya and Huang, Xiaojie and Ye, Chen and Zhang, Zongfeng and Li, Lutong and Zhu, Wenli and Zhang, Zhaofeng and He, Lixia},
title = {Anti-Hyperuricemic Effect of Anserine Based on the Gut–Kidney Axis: Integrated Analysis of Metagenomics and Metabolomics},
journal = {Nutrients},
year = {2023},
doi = {10.3390/nu15040969}
}
EUVIMED